Asia Pacific Oncology Based Molecular Diagnostics Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Lung Cancer), By Product (Instruments, Reagents), By Technology (PCR, Sequencing), By Region, And Segment Forecasts, 2025

The Asia Pacific oncology based molecular diagnostics market size was estimated at USD 822.5 million in 2024 and is projected to reach USD 1,560.75 million by 2033, growing at a CAGR of 6.8% from 2025 to 2033. Rising cancer burden across breast, prostate, and colon, along with the aging population, is driving the demand for effective diagnostic solutions in the region. Advancements in technology, the growing adoption of point-of-care testing (POCT), and developments in biomarker identification systems are supporting market expansion. In addition, government initiatives aimed at cancer screening and early detection, as well as increased healthcare investments across emerging economies, are contributing to the rising demand for molecular diagnostics.

The increasing requirement for accurate and rapid testing methods and the growing integration of Next-Generation Sequencing (NGS) techniques for oncology diagnostics further support the market. Awareness of personalized medicine and the adoption of targeted treatment strategies are also influencing market trends. Expanding research and development efforts and collaborations to develop innovative molecular diagnostic solutions are expected to strengthen the regional market outlook through 2033.

Growing healthcare infrastructure, particularly in countries like China, India, and Japan, is boosting the accessibility and adoption of advanced diagnostic technologies. Rising partnerships between diagnostic laboratories and healthcare institutions and the focus on early cancer detection programs are fostering regional growth. Furthermore, the increasing shift toward non-invasive testing methods, such as liquid biopsies, and the availability of advanced genetic testing platforms are expected to create significant opportunities for the market in the coming years.

Overall, the Asia Pacific market is evolving with innovations like liquid biopsies, advanced NGS platforms, AI-driven analytics, and portable molecular testing devices that make cancer detection faster and more accurate. Introducing multi-omics approaches and strategic collaborations further supports personalized treatment and early detection initiatives. However, factors such as high costs of advanced technologies, uneven access across rural areas, and regulatory complexities may influence the pace of widespread adoption in the region.

Asia Pacific Oncology Based Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the Asia Pacific oncology based molecular diagnostics Market based on product, technology, type, and country:

Type Outlook (Revenue, USD Million, 2021 - 2033)
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Liver Cancer
Lung Cancer
Blood Cancer
Kidney Cancer
Others
Product Outlook (Revenue, USD Million, 2021 - 2033)
Instruments
Reagents
Others
Technology Outlook (Revenue, USD Million, 2021 - 2033)
PCR
In situ hybridization
INAAT
Chips and microarrays
Mass spectrometry
Sequencing
TMA
Others
Country Outlook (Revenue, USD Million, 2021 - 2033)
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand

Product Code: GVR-4-68040-201-5

Chapter 1. Asia Pacific Oncology Based Molecular Diagnostics Market: Methodology and Scope

1.1. Market Segmentation and Scope
- 1.1.1. Segment Definitions
  - 1.1.1.1. Type Segment
  - 1.1.1.2. Product Segment
  - 1.1.1.3. Technology segment
1.2. Country Scope
1.3. Estimates and Forecast Timeline
1.4. Objectives
- 1.4.1. Objective - 1
- 1.4.2. Objective - 2
- 1.4.3. Objective - 3
1.5. Research Methodology
1.6. Information Procurement
- 1.6.1. Purchased Database
- 1.6.2. GVR's Internal Database
- 1.6.3. Secondary Sources
- 1.6.4. Primary Research
1.7. Information or Data Analysis
- 1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
- 1.9.1. Commodity Flow Analysis
1.10. List of Secondary Sources
1.11. List of Abbreviations

Chapter 2. Asia Pacific Oncology Based Molecular Diagnostics Market: Executive Summary

2.1. Market Snapshot
2.2. Type and Product Snapshot
2.3. Technology Snapshot
2.4. Competitive Landscape Snapshot

Chapter 3. Asia Pacific Oncology Based Molecular Diagnostics Market Variables, Trends, & Scope

3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
- 3.2.1. Parent Market Outlook
- 3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers Analysis
- 3.4.1. Rising Global Cancer Prevalence
- 3.4.2. Adoption of Precision Medicine
- 3.4.3. Advances in Molecular Testing Technologies
3.5. Market Restraint Analysis
- 3.5.1. High Costs of Testing and Equipment
- 3.5.2. Inconsistent Reimbursement and Regulatory Frameworks
- 3.5.3. Limited Access in Low-Resource Regions
3.6. Porter's Five Forces Analysis
3.7. PESTLE Analysis
3.8. Pipeline Analysis

Chapter 4. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis

4.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Movement Analysis
4.2. Breast Cancer
- 4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.3. Prostate Cancer
- 4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4. Colorectal Cancer
- 4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Cervical Cancer
- 4.5.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Liver Cancer
- 4.6.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.7. Lung Cancer
- 4.7.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.8. Blood Cancer
- 4.8.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.9. Kidney Cancer
- 4.9.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.10. Others
- 4.10.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis

5.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Movement Analysis
5.2. Instruments
- 5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.3. Reagents
- 5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
5.4. Others
- 5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis

6.1. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Movement Analysis
6.2. PCR
- 6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3. In situ hybridization
- 6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. INAAT
- 6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Chips and microarrays
- 6.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Mass spectrometry
- 6.6.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. Sequencing
- 6.7.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.8. TMA
- 6.8.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
6.9. Others
- 6.9.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Asia Pacific Oncology Based Molecular Diagnostics Market: Country Business Analysis

7.1. Country Market Snapshot
7.2. Asia Pacific
- 7.2.1. Asia Pacific Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
- 7.2.2. Japan
  - 7.2.2.1. Japan Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.2.2.2. Key Country Dynamics
  - 7.2.2.3. Regulatory Framework
  - 7.2.2.4. Reimbursement Scenario
  - 7.2.2.5. Competitive Scenario
- 7.2.3. China
  - 7.2.3.1. China Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.2.3.2. Key Country Dynamics
  - 7.2.3.3. Regulatory Framework
  - 7.2.3.4. Reimbursement Scenario
  - 7.2.3.5. Competitive Scenario
- 7.2.4. India
  - 7.2.4.1. India Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.2.4.2. Key Country Dynamics
  - 7.2.4.3. Regulatory Framework
  - 7.2.4.4. Reimbursement Scenario
  - 7.2.4.5. Competitive Scenario
- 7.2.5. Australia
  - 7.2.5.1. Australia Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.2.5.2. Key Country Dynamics
  - 7.2.5.3. Regulatory Framework
  - 7.2.5.4. Reimbursement Scenario
  - 7.2.5.5. Competitive Scenario
- 7.2.6. New Zealand
  - 7.2.6.1. New Zealand Oncology Based Molecular Diagnostics Market, 2021 - 2033 (USD Million)
  - 7.2.6.2. Key Country Dynamics
  - 7.2.6.3. Regulatory Framework
  - 7.2.6.4. Reimbursement Scenario
  - 7.2.6.5. Competitive Scenario

Chapter 8. Competitive Landscape

8.1. Company Categorization
8.2. Strategy Mapping
- 8.2.1. New Type Launch
- 8.2.2. Partnerships
- 8.2.3. Acquisiton
- 8.2.4. Collaboration
- 8.2.5. Funding
8.3. Key Company Market Share Analysis, 2024
8.4. Company Heat Map Analysis
8.5. Company Profiles
- 8.5.1. Abbott
  - 8.5.1.1. Company Overview
  - 8.5.1.2. Financial Performance
  - 8.5.1.3. Type Benchmarking
  - 8.5.1.4. Strategic Initiatives
- 8.5.2. Agilent Technologies, INC.
  - 8.5.2.1. Company Overview
  - 8.5.2.2. Financial Performance
  - 8.5.2.3. Type Benchmarking
  - 8.5.2.4. Strategic Initiatives
- 8.5.3. bioMerieux SA
  - 8.5.3.1. Company Overview
  - 8.5.3.2. Financial Performance
  - 8.5.3.3. Type Benchmarking
  - 8.5.3.4. Strategic Initiatives
- 8.5.4. Danaher
  - 8.5.4.1. Company Overview
  - 8.5.4.2. Financial Performance
  - 8.5.4.3. Type Benchmarking
  - 8.5.4.4. Strategic Initiatives
- 8.5.5. F. Hoffmann-La Roche Ltd.
  - 8.5.5.1. Company Overview
  - 8.5.5.2. Financial Performance
  - 8.5.5.3. Type Benchmarking
  - 8.5.5.4. Strategic Initiatives
- 8.5.6. ILLUMINA
  - 8.5.6.1. Company Overview
  - 8.5.6.2. Financial Performance
  - 8.5.6.3. Type Benchmarking
  - 8.5.6.4. Strategic Initiatives
- 8.5.7. Novartis AG
  - 8.5.7.1. Company Overview
  - 8.5.7.2. Financial Performance
  - 8.5.7.3. Type Benchmarking
  - 8.5.7.4. Strategic Initiatives
- 8.5.8. QIAGEN
  - 8.5.8.1. Company Overview
  - 8.5.8.2. Financial Performance
  - 8.5.8.3. Type Benchmarking
  - 8.5.8.4. Strategic Initiatives
- 8.5.9. Siemens Healthineers AG
  - 8.5.9.1. Company Overview
  - 8.5.9.2. Financial Performance
  - 8.5.9.3. Type Benchmarking
  - 8.5.9.4. Strategic Initiatives
- 8.5.10. TBG Diagnostics Limited
  - 8.5.10.1. Company Overview
  - 8.5.10.2. Financial Performance
  - 8.5.10.3. Type Benchmarking
  - 8.5.10.4. Strategic Initiatives
- 8.5.11. Thermo Fisher Scientific Inc
  - 8.5.11.1. Company Overview
  - 8.5.11.2. Financial Performance
  - 8.5.11.3. Type Benchmarking
  - 8.5.11.4. Strategic Initiatives
- 8.5.12. Sysmex
  - 8.5.12.1. Company Overview
  - 8.5.12.2. Financial Performance
  - 8.5.12.3. Type Benchmarking
  - 8.5.12.4. Strategic Initiatives

Product Code: GVR-4-68040-201-5

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviation
Table 3 Asia Pacific Oncology Based Molecular Diagnostics Market, by country, 2021 - 2033 (USD Million)
Table 4 Asia Pacific Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 5 Asia Pacific Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 6 Asia Pacific Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 7 Japan Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 8 Japan Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 9 Japan Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 10 China Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 11 China Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 12 China Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 13 India Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 14 India Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 15 India Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 16 Australia Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 17 Australia Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 18 Australia Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)
Table 19 New Zealand Oncology Based Molecular Diagnostics Market, by Technology, 2021 - 2033 (USD Million)
Table 20 New Zealand Oncology Based Molecular Diagnostics Market, By Type, 2021 - 2033 (USD Million)
Table 21 New Zealand Oncology Based Molecular Diagnostics Market, By Product, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market summary
Fig. 4 Market segmentation & scope
Fig. 5 Market size and growth prospects
Fig. 6 Asia Pacific Oncology Based Molecular Diagnostics Market: Key Market Driver Analysis
Fig. 7 Asia Pacific Oncology Based Molecular Diagnostics Market: Key Market Restraint Analysis
Fig. 8 Penetration & growth prospect mapping
Fig. 9 Asia Pacific Oncology Based Molecular Diagnostics Market: Porter's analysis
Fig. 10 Asia Pacific Oncology Based Molecular Diagnostics Market: PESTEL analysis
Fig. 11 Asia Pacific Oncology Based Molecular Diagnostics Market type outlook key takeaways
Fig. 12 Asia Pacific Oncology Based Molecular Diagnostics Market: Type movement analysis
Fig. 13 Breast Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 14 Prostate Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 15 Colorectal Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 16 Cervical Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 17 Liver Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 18 Lung Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 19 Blood Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 20 Kidney Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 21 Others Cancer market estimates, 2021 - 2033 (USD Million)
Fig. 22 Asia Pacific Oncology Based Molecular Diagnostics Market product outlook key takeaways
Fig. 23 Asia Pacific Oncology Based Molecular Diagnostics Market: Product Movement Analysis
Fig. 24 Instruments market estimates, 2021 - 2033 (USD Million)
Fig. 25 Reagents market estimates, 2021 - 2033 (USD Million)
Fig. 26 Others market estimates, 2021 - 2033 (USD Million)
Fig. 27 Asia Pacific Oncology Based Molecular Diagnostics Market technology outlook key takeaways
Fig. 28 Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Movement Analysis
Fig. 29 PCR market estimates, 2021 - 2033 (USD Million)
Fig. 30 In situ hybridization market estimates, 2021 - 2033 (USD Million)
Fig. 31 INAAT market estimates, 2021 - 2033 (USD Million)
Fig. 32 Chips and microarrays market estimates, 2021 - 2033 (USD Million)
Fig. 33 Mass spectrometry market estimates, 2021 - 2033 (USD Million)
Fig. 34 Sequencing market estimates, 2021 - 2033 (USD Million)
Fig. 35 TMA market estimates, 2021 - 2033 (USD Million)
Fig. 36 Others market estimates, 2021 - 2033 (USD Million)
Fig. 37 Country marketplace: Key takeaways
Fig. 38 Asia Pacific Oncology Based Molecular Diagnostics Market: Country movement analysis
Fig. 39 Asia Pacific oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 40 Japan oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 41 China oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 42 India oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 43 Australia oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 44 New Zealand oncology based molecular diagnostics market, 2021 - 2033 (USD Million)
Fig. 45 Strategy framework

Asia Pacific Oncology Based Molecular Diagnostics Market Size, Share & Trends Analysis Report By Type (Breast Cancer, Lung Cancer), By Product (Instruments, Reagents), By Technology (PCR, Sequencing), By Region, And Segment Forecasts, 2025 - 2033

Description

Table of Contents

List of Tables

Market Size & Trends:

Table of Contents

Chapter 1. Asia Pacific Oncology Based Molecular Diagnostics Market: Methodology and Scope

Chapter 2. Asia Pacific Oncology Based Molecular Diagnostics Market: Executive Summary

Chapter 3. Asia Pacific Oncology Based Molecular Diagnostics Market Variables, Trends, & Scope

Chapter 4. Asia Pacific Oncology Based Molecular Diagnostics Market: Type Estimates & Trend Analysis

Chapter 5. Asia Pacific Oncology Based Molecular Diagnostics Market: Product Estimates & Trend Analysis

Chapter 6. Asia Pacific Oncology Based Molecular Diagnostics Market: Technology Estimates & Trend Analysis

Chapter 7. Asia Pacific Oncology Based Molecular Diagnostics Market: Country Business Analysis

Chapter 8. Competitive Landscape

List of Tables

List of Figures